Technology | March 19, 2013

Terumo Expands Radial-Specific Family of Heartrail III Coronary Guiding Catheters

A lower profile guiding catheter ideally suited for treating interventions in smaller stature patients

March 19, 2013 — Terumo Interventional Systems expanded its family of Heartrail III Coronary Guiding Catheters to include a smaller profile 5 French Ikari shape, specifically designed to provide backup support and access to target coronary lesions during transradial catheterizations.  The smaller 5 French Heartrail is designed to help physicians achieve access to the coronary arteries using a smaller-diameter catheter platform, and proprietary Ikari tip shapes, while providing the backup support and body of a traditionally larger French size catheter.

The smaller size enhances the Heartrail III guiding catheter portfolio by providing various options in response to guide catheter support needs during transradial catheterizations. Benefits include:

  • Proprietary outer surface treatment, to reduce friction between the catheter and inner lumen of the artery.
  • Flexible shaft design, for optimal trackability, even in tortuous vessels.
  • Efficient torque control, providing smooth handling and accurate engagement of the artery.
  • High radiopacity, for enhanced visibility that allows accurate tip positioning in the coronary ostium.
  • Bigger lumen size, to reduce device friction for ease of device manipulation.

Transradial catheterization is used to gain access to the heart through the arteries of the wrist, rather than the groin. It is the leading access strategy in many countries of the world and while the technique accounts for an estimated 15-20 percent of cases in the United States, there is a growing interest among physicians for more specialized tools that facilitate the procedure.

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init